Dublin, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The "Advanced Pharmacovigilance Training Course" conference has been added to ResearchAndMarkets.com's offering.
Pharmacovigilance has undergone rapid regulatory change in recent years, which has resulted in a complex range of safety and risk assessment activities to perform. This three-day course is designed for those with at least two years of knowledge in drug safety and will provide a comprehensive, yet practical assessment of the main regulations required to produce a compliant reporting company.
Key topics to be addressed:
- Audits and expectations - risk-based inspections
- Compliance and drug safety
- Overview of the PSMF in the EU
- Product safety reviews - purpose and function (incorporating the latest EU signal analysis requirements)
- Safety reporting in licensing agreements
- Developing company core safety information (CCSI) - CIOMS III
- PSURs - timing, content and the DSUR and the latest ICH E2C (2nd revision requirements)
- Implications for safety reporting in global clinical trials
- Risk-benefit determinations
- Risk management plans (RMPs)
By attending this event, you will:
- Expand your global safety knowledge
- Enhance your team's capabilities and compliance in both the regulations and your company's expectations
- Help ensure you build and maintain a quality pharmacovigilance department ready for any pharmacovigilance inspection
- Participate in group workshop sessions and discuss how to apply the legislation to ensure compliance, especially to satisfy regulatory inspections
Certification:
- CPD: 18 hours for your records
- Certificate of completion
Who Should Attend:
This course would be of maximum benefit to those safety professionals who are working both in the clinical and post-marketing safety arena including QA for auditing. The course covers very diverse activities within the safety department and would be advantageous to those who have either multifunction responsibilities or medical directors who manage teams in the various disciplines.
Agenda:
Due diligence
- Due diligence on products/companies (partners and acquisitions)
- Due diligence involvement - team composition
- Safety information requirements for due diligence
- Review of safety data (clinical and post-marketing)
- Defining risk in due diligence appraisals
Training for drug safety reporting duties
- Regulations concerning safety training
- Who trains whom and when?
- Training versus job description
- Training records, maintenance and updates
- Role of QA and HR in training
Audits and expectations
- Regulatory expectations in pharmacovigilance audits (risk-based inspections)
- Preparation for the audit
- Records to be available at the audit
- Audit findings/recommendations
Compliance and drug safety
- Basic principles - what will the regulators want to see?
- Measuring compliance
- Quality versus quantity in safety reports
- Future aspects in ensuring efficient compliance
- Quality management under the new EU legislation
The PSMF
- The PSMF - purpose and maintenance
- ThePSMFannexes
- ThePSMFand audits
Interactive exercise: The requirements for a safety department
Product safety reviews - purpose and function
- The Safety Review Committee (SRC)
- What to look for in signal evaluation under latest EU guidance
- Timings for safety review in clinical and post-marketed products
- Record keeping for safety review meetings
- Serious safety findings - crisis management following new safety findings
Interactive exercise: Designing the requirements for a safety review group
Safety reporting in licensing agreements
- What types of licensing agreements exist?
- What are the EU andFDAregulations concerning licensing agreements?
- Audits of pharmacovigilance capabilities in licensing partners
- What agreements need to be in place for safety reporting?
- Safety reporting agreements - what needs to be covered?
- Monitoring safety agreements - what happens if it goes wrong?
Developing CCSI - CIOMS III
- CIOMSIIIandCCSI
- Developmental core safety information (DCSI)
- How to determine what to include and what to exclude inDCSI/CCSI
- Are there differences in EU andFDA?
- Maintenance and development ofCCSI
Interactive exercise: Should new safety data from a clinical trial be put into core safety information?
PSURs and the revisions in ICH E2C
- Timing forPSURs
- PSURcontent and latest format
- Late breaking information andPSURextensions
- TheDSUR
The EU Clinical Trials Directive
- The principles of the Directive
- Implications for safety reporting in global clinical trials
- TheSUSARdatabase
- TheEUDRACTdatabase
- The new EU Clinical Trial Regulation
Risk-benefit determinations
- Definitions of risk-benefit - FDA and EU perspective
- Risk-benefit assessments - who does this and where does the information go?
- Safety assessments and risk-benefit - frequency and reporting
- Changes in risk-benefit - how to manage and review existing profiles
Risk-benefit determinations
- Definitions of risk-benefit - FDA and EU perspective
- Risk-benefit assessments - who does this and where does the information go?
- Safety assessments and risk-benefit - frequency and reporting
- Changes in risk-benefit - how to manage and review existing profiles
Interactive exercise: Reviewing the safety and risk-benefit of a product
RMPs
- Purpose
- Content
- Monitoring and updating theRMP
- Reporting theRMP
Crisis management within drug safety
- Regulations and guidelines in connection with serious safety issues
- What determines a crisis?
- Communications to regulators - what is required?
- Communications within the company
- What happens next?
Interactive exercise: Deciding how to handle a major crisis within the company
Delegates will be split into groups and present what they need to have in place in order to effectively manage the crisis and look to its resolution.
For more information about this conference visit https://www.researchandmarkets.com/r/w2b9zi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
